[go: up one dir, main page]

WO2008013928A3 - Traitement du cancer par administration de gène interféron en association avec un inhibiteur tgf-beta - Google Patents

Traitement du cancer par administration de gène interféron en association avec un inhibiteur tgf-beta Download PDF

Info

Publication number
WO2008013928A3
WO2008013928A3 PCT/US2007/016880 US2007016880W WO2008013928A3 WO 2008013928 A3 WO2008013928 A3 WO 2008013928A3 US 2007016880 W US2007016880 W US 2007016880W WO 2008013928 A3 WO2008013928 A3 WO 2008013928A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
tgf
cancer
combination
gene delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/016880
Other languages
English (en)
Other versions
WO2008013928A2 (fr
Inventor
Michael Parr
Leona Ling
Steven Albelda
Samuel Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
University of Pennsylvania Penn
Biogen MA Inc
Original Assignee
University of Pennsylvania Penn
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Biogen Idec Inc, Biogen Idec MA Inc filed Critical University of Pennsylvania Penn
Publication of WO2008013928A2 publication Critical patent/WO2008013928A2/fr
Publication of WO2008013928A3 publication Critical patent/WO2008013928A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés de traitement du cancer comprenant l'administration à un sujet nécessitant le traitement, une multithérapie comprenant (a) l'administration d'un inhibiteur TGF-β et (b) un vecteur comprenant un polynucléotide isolé qui code un polypeptide interféron.
PCT/US2007/016880 2006-07-28 2007-07-27 Traitement du cancer par administration de gène interféron en association avec un inhibiteur tgf-beta Ceased WO2008013928A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83377206P 2006-07-28 2006-07-28
US60/833,772 2006-07-28

Publications (2)

Publication Number Publication Date
WO2008013928A2 WO2008013928A2 (fr) 2008-01-31
WO2008013928A3 true WO2008013928A3 (fr) 2008-10-30

Family

ID=38982092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016880 Ceased WO2008013928A2 (fr) 2006-07-28 2007-07-27 Traitement du cancer par administration de gène interféron en association avec un inhibiteur tgf-beta

Country Status (1)

Country Link
WO (1) WO2008013928A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750559A1 (fr) * 2009-02-05 2010-08-12 Digna Biotech, S.L. Formulations pharmaceutiques de peptides inhibiteurs de tgf-.beta.1
US8951521B2 (en) * 2010-08-30 2015-02-10 Riken Compounds having activity of suppressing activation of TGF-β receptor, method for screening of the compounds, and composition for preventing or treating disease caused by hepatitis C virus
BR112023015303A2 (pt) 2021-02-01 2023-11-14 Regenxbio Inc Método para tratar doença cln2 devido a deficiência de tpp1 em um sujeito

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL.: "Adeno-associated virus mediated interferon-gamma inhibits the progression of heptic fibrosis in vitro and in vivo", WORLD GARTROENTEROL., vol. 12, no. 26, 2005, pages 4045 - 4051, XP008103910 *
CURTIN ET AL.: "Combining cytotoxic and immune-mediated gene therapy to treat brain tumor", CURR. TOP. MED. CHEM., vol. 5, no. 12, 2005, pages 1151 - 1170 *
HJELMELAND ET AL.: "SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glimo cell line proliferation and mitility", MOL. CANCER THER., vol. 3, no. 6, 2004, pages 737 - 745 *
ZHANG ET AL.: "Blockage of transforming growth factor-beta signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle", MOL. CANCER THER., vol. 5, no. 7, 2006, pages 1733 - 1745 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US8415345B2 (en) 2008-05-06 2013-04-09 Glaxo SmithKline LLC Benzene sulfonamide thiazole and oxazole compounds
US8642759B2 (en) 2008-05-06 2014-02-04 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds

Also Published As

Publication number Publication date
WO2008013928A2 (fr) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2007113648A3 (fr) Polythérapie à base d'un anticorps anti-ctla4
WO2011053991A3 (fr) Complexes vault pour l'administration de cytokine
WO2007146426A3 (fr) Nanobilles pour délivrance de médicament
WO2008143954A3 (fr) Régions fc simple chaîne, polypeptides de liaison comportant de telles régions, et procédés correspondants
WO2003000928A3 (fr) Innovation en matiere de therapie anti-cancereuse
WO2008091375A3 (fr) Salmonella atténuée en tant que système de distribution pour une thérapie de tumeur à base d'arnsi
IL172223A0 (en) Drug delivery systems for tumor targeting ngr-molecules and uses thereof
WO2006083971A3 (fr) Anticorps dr5 et utilisations de ceux-ci
WO2007103666A3 (fr) Systèmes de livraison d'endoprothèse médicale implantable
WO2007064945A3 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
WO2008036929A3 (fr) Complexe permettant de tansférer une substance anionique dans une cellule
EP3895725A3 (fr) Procédé de traitement de tumeurs au moyen d'interféron recombinant à configuration spatiale modifiée
WO2014006502A8 (fr) Protéines de surface spécifiques d'un variant de protozoaire (vsp) utilisées comme transporteurs pour l'administration de médicaments par voie orale
WO2008016633A3 (fr) Thérapie par combinaison
WO2011156453A3 (fr) Peptides thérapeutiques
WO2006041641A3 (fr) Agents therapeutiques a toxicite reduite
WO2007092944A3 (fr) Compositions et procedes impliquant une therapie de gene et une modulation de proteasome
WO2007093373A3 (fr) Peptides multimeres branches pour un diagnostic de tumeur et une therapie
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2008013928A3 (fr) Traitement du cancer par administration de gène interféron en association avec un inhibiteur tgf-beta
WO2010099139A3 (fr) Thérapie anti-cancer combinée
WO2008134752A3 (fr) Méthodes et compositions pour traiter le cancer
WO2007107748A3 (fr) Inhibition de la croissance tumorale
WO2009138507A3 (fr) Thérapie combinée contre le cancer
WO2006027693A3 (fr) Genes et arn variants specifiques de tumeur et leurs utilisations comme cibles pour le traitement et le diagnostic du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836279

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07836279

Country of ref document: EP

Kind code of ref document: A2